Processa Pharmaceuticals Completes $5 Million Public Offering
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), a pioneering clinical-stage pharmaceutical company dedicated to enhancing cancer treatment options, recently finalized a significant public offering, drawing in $5 million in gross proceeds. This offering stems from the company's ongoing commitment to develop next-generation chemotherapy drugs that emphasize both safety and effectiveness.
Details of the Offering
In this move, Processa's recent public offering included 8,050,672 shares of common stock, with alternative options available such as pre-funded warrants, and a series of accompanying warrants designed for institutional investors. Alongside, it offers Series A warrants that allow for the purchase of the same number of common shares and Series B warrants for an additional 4,025,336 shares. The pricing was strategically set at $0.615 per share for institutional investors and $0.7975 for key figures within the company, including the Chief Executive Officer and certain members of the board.
Successful Execution and Financial Outcome
The conclusion of the offering took place shortly after the stock market’s close, further solidifying Processa's position in the industry. Prior to deduction of placement agent fees and other expenses related to the offering, a total of $5 million was raised. A.G.P./Alliance Global Partners operated as the sole placement agent, further exemplifying their trust in the company's vision.
Regulatory and Legal Compliance
All transactions were conducted in compliance with the necessary regulatory procedures. The Securities and Exchange Commission (SEC) reviewed and approved a registration statement pertaining to this offering, ensuring that all legal requirements were met. It went effective shortly before the public offering, underscoring the company's robust attention to regulatory oversight.
Company Vision and Strategy
Processa prides itself on its innovative approach to developing chemotherapy drugs. The company's strategic framework revolves around modifying existing FDA-approved oncology drugs to not only enhance their effectiveness in treating cancer but also to improve safety profiles. This dual focus significantly aids in creating more tolerable therapy options for patients facing the challenges of cancer treatment.
Future Directions and Commitment to Patients
As Processa moves forward, the integration of advanced regulatory science into their development process aims to streamline the path to new chemotherapy solutions. By doing so, Processa will continue to advocate for more effective and patient-friendly cancer treatments.
Contact Information for Stakeholders
For those interested in learning more about Processa Pharmaceuticals or the latest updates on their offerings, the company maintains an open line of communication. Patrick Lin, who is a key contact for any inquiries, can be reached at (925) 683-3218 or through email at plin@processapharma.com.
Investor Relations
Yvonne Briggs leads the investor relations docket for Processa and is available to assist interested parties at (310) 691-7100. Additionally, she can be reached via email at ybriggs@allianceadvisors.com.
Frequently Asked Questions
What is the purpose of Processa Pharmaceuticals' recent offering?
The offering aims to raise funds to further develop next-generation chemotherapy drugs with a focus on improving safety and efficacy.
Who participated in the public offering?
The offering attracted participation from the CEO, board members, and existing institutional investors focused on healthcare.
What is the price per share in the offering?
The shares were priced at $0.615 for institutional investors and $0.7975 for the company’s executive team.
How much total proceeds were raised from the offering?
A total of $5 million was raised in gross proceeds before deducting associated fees and expenses.
What is the focus of Processa Pharmaceuticals?
The company is focused on developing chemotherapy drugs that enhance effectiveness while maintaining safety for patients.
